Axelmark is asking shareholders to approve a financing package that would do two jobs at once, inject up to ¥3.9bn of funding and hand control of the company to Convano. Under plans approved on May 29, Convano would subscribe for 45 million new shares at ¥20 each, a ¥900m equity injection, while also providing a commitment-type term loan facility of up to ¥3bn. Axelmark says the equity and debt pieces are inseparable and should be judged as one funding framework.
If the deal closes on July 2, Convano would become Axelmark’s largest shareholder, parent company and controlling shareholder. Axelmark’s supplemental materials say Convano would hold 68.91% of voting rights after the allotment, leaving existing investors with 31.09%. The dilution is extreme even by Growth-market standards: Axelmark disclosed dilution of 221.53% against shares outstanding and 221.60% against voting rights, which is why it is seeking both a special resolution on the favorable issuance and a separate shareholder-intent confirmation vote.
The debt leg matters almost as much as the equity leg. Axelmark says the loan facility is effective on signing, but each drawdown still depends on the contract’s conditions being met. In the supplemental deck, the company describes the facility as a fixed-rate 2.0% line with a five-year lending availability period, earmarked for healthcare-sector M&A and related business investment. That helps explain why this is more than a simple placement: Axelmark is trying to replace a shrinking financing menu with a strategic backer that can supply both capital and transaction support. The company says it reviewed alternatives including a public offering, a rights issue, extra bank borrowing and more warrants, and concluded that a third-party allotment plus debt from an operating company was the only practical route.
The control shift is also showing up in governance. On the same day, Axelmark proposed six new board members for the July 2 extraordinary meeting. Among the non-audit director nominees are Riki Itataka, currently a Convano director, Reo Yokoya, now a Convano executive officer, and Yumi Saito, Convano’s head of corporate planning office and an executive officer. Tatsunori Saka previously served as an executive officer at Convano consulting. In other words, the funding package does not just refinance Axelmark, it sketches the management structure of a Convano-backed subsidiary.
The catch is timing and conditions. Axelmark says the share issue will not proceed unless shareholders approve the large dilution, the control change and the favorable issuance at the July 2 meeting, and unless the securities filing becomes effective. If those conditions fail, the company says it will revisit alternative measures and financing. The loan facility, meanwhile, exists on paper today but still needs drawdown conditions to be met before cash can move.